[Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
The efficacy of biologics targeting inflammatory cytokines such as TNF and IL-6 for bone and joint diseases has been emerging. Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damage. By the use of TNF-inhibitors, clinical remission, structural remission and functional remission have become possible during the treatment of RA. Especially, the progress of joint and bone destruction is completely suppressed by TNF-inhibitors in the vast majority of RA patients. On the other hand, anti-RANKL antibody inhibits joint destruction as well as systemic osteoporosis, though no effects on synovitis of RA. Thus, differential efficacy of different therapies in bone destruction and osteoporosis would warrant further study to clarify the mechanisms of bone and joints diseases.
Tanaka
Yoshiya
Y
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology / Q000502:physiology; D007592:Joint Diseases / Q000188:drug therapy* / Q000209:etiology; D058990:Molecular Targeted Therapy; D010024:Osteoporosis / Q000188:drug therapy; D053245:RANK Ligand / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha